Biogen Inc (NASDAQ:BIIB) is ranked as a Hold using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. BIIB has maintained this ranking for 2 months.

Biogen Inc (NASDAQ:BIIB) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. BIIB's market value is $66.4 billion which places it in the top decile in its industry group. Portfolio Grader's current ranking for BIIB puts it 142 among the 349 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 349 among the 781 companies in the sector, and number 2,252 in the nearly 5,000 company Portfolio Grader universe.

Biogen Inc (NASDAQ:BIIB) is classified as a constituent of the 349 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. BIIB's market value is $65.7 billion which falls in the top 10% of its industry group. The ranking for BIIB by Portfolio Grader places it 145 among the 349 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 351 among the 782 companies in the sector, and number 2,233 in the nearly 5,000 company Portfolio Grader universe.

Biogen Inc (NASDAQ:BIIB) is ranked as a Hold using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BIIB has had from Portfolio Grader for 2 months.

The current recommendation of Hold for Biogen Inc (NASDAQ:BIIB) is computed using Louis Navellier's methods for investing and his Portfolio Grader stock evaluator. BIIB has maintained this ranking for the last month.

Portfolio Grader currently ranks Biogen Inc (NASDAQ:BIIB) a Hold. Using Louis Navellier's investing methodology, this analytical tool researches stocks by employing proprietary fundamental and quantitative metrics. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Biogen Inc (NASDAQ:BIIB) is ranked as a Hold using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BIIB has had from Portfolio Grader for the last month.

Portfolio Grader currently ranks Biogen Inc (NASDAQ:BIIB) a Hold. Using Louis Navellier's investing methods, this analytical tool assesses stocks by employing proprietary fundamental and quantitative analytical tools. BIIB has been upgraded from a Sell to a Hold in the last week.

Portfolio Grader currently ranks Biogen Inc (NASDAQ:BIIB) a Hold. Using Louis Navellier's investing methods, this analytical tool assesses stocks by employing proprietary fundamental and quantitative analytical tools. BIIB has been upgraded from a Sell to a Hold in the last week.